Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAspirin and semaglutide can generally be taken together. There is no pharmacokinetic interaction between them that prevents concurrent use, and many people prescribed Wegovy or another semaglutide medicine already take low-dose aspirin for heart health. That said, both medicines affect the gut in different ways, and your prescriber should know about every medicine you take before treatment begins. Semaglutide is a prescription-only medicine, so any decision about combining it with other drugs rests with a clinician who has reviewed your full medical history.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors in the gut and brain. One of its most clinically significant effects is slowing gastric emptying, food moves from your stomach into your small intestine more slowly than usual. This contributes to the feeling of fullness that helps reduce calorie intake over time.
The slowing of gastric emptying matters for other oral medicines because absorption timing can shift. For most drugs taken at standard doses, this is clinically inconsequential. Aspirin at the low doses used for cardiovascular protection (typically 75 mg daily in the UK) is absorbed reliably even when gastric transit is slowed, and no specific interaction warning exists for this combination in the BNF's semaglutide monograph.
Where the picture is slightly different is with higher doses of aspirin, for example, those used during an acute illness or for pain relief. At those doses, combined gastric irritation becomes a more relevant consideration. Semaglutide can cause nausea, indigestion and reflux, particularly in the first weeks of a new dose, and aspirin taken at analgesic doses on top of that can make stomach discomfort noticeably worse for some people. If you find your stomach is unsettled, it is worth reading up on semaglutide and aspirin interactions before mentioning your aspirin use to whoever oversees your semaglutide treatment. They are best placed to advise on timing and dose.
This question comes up because many people starting treatment with Wegovy already take low-dose aspirin. Cardiovascular disease is one of the weight-related conditions that can make a person eligible for semaglutide under its UK licence, and low-dose aspirin is a cornerstone of secondary prevention for heart attack and stroke. So the combination is not unusual, it reflects the overlap between the populations these medicines serve.
If you take aspirin for a diagnosed cardiovascular condition, there is no need to stop it when starting semaglutide. Stopping antiplatelet therapy without medical advice carries its own risks. If you would like to understand more about how these two medicines interact specifically, our page on aspirin and Wegovy goes into further detail that may be useful before your next prescriber conversation. If you take aspirin informally (say, as a general health supplement or for occasional pain) it is worth discussing that habit with your prescriber anyway, because the evidence for aspirin as a preventive measure in people without established cardiovascular disease has shifted in recent years. That conversation is worth having irrespective of semaglutide.
A more detailed look at the broader question of medicines to avoid or review when taking semaglutide covers a wider range of drug classes, including oral contraceptives and medicines with a narrow therapeutic window, where the gastric-emptying effect is more clinically significant.
If you already take aspirin and are considering semaglutide through a regulated service such as ours at nume, your consultation is the right place to disclose it. Our prescribers review each person's medication list as part of that assessment. It takes seconds to mention, and it means the clinical decision about your treatment is made on complete information.
The same applies in reverse. If you have been prescribed semaglutide and your GP subsequently suggests starting low-dose aspirin, tell them you are on a GLP-1 medicine. This is not because the combination is dangerous, but because good prescribing requires the full picture. The NHS medicines guidance on semaglutide advises patients to share their full medicine list, including over-the-counter medicines, with any clinician who prescribes for them.
We understand that juggling multiple medicines can feel complicated, especially when you are also adjusting to a new treatment and trying to manage side effects. That is why aftercare access matters. If you have questions about a specific medicine and semaglutide after starting treatment, our clinical team is available seven days a week to help you think it through rather than leaving you to search online for reassurance.
For a broader overview of what life on semaglutide looks like and how the medicine works, the semaglutide information page covers the mechanism, the titration schedule, and what to expect in the early weeks. If you are weighing up whether Wegovy is suitable for you specifically, the eligibility guide runs through the clinical criteria in plain terms. And if you are ready to speak with a prescriber directly, you can start a free consultation with the nume team any time.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.